Rantum Capital supports Cinven’s public acquisition offer for SYNLAB AG
Rantum Capital is pleased to announce its participation as a direct lender in the financing of Cinven’s public acquisition offer for SYNLAB AG via Rantum Private Debt Fund III.
As announced on 29 September 2023, Cinven has launched a public acquisition offer for all outstanding shares of SYNLAB, a leading provider of laboratory diagnostic services for practising doctors, clinics and patients. Headquartered in Munich, Germany, SYNLAB operates in 33 countries across four continents and is a core provider to many national healthcare systems.
Rantum Capital has committed to provide a portion of the acquisition financing alongside other leading financial institutions.
“We are excited to support Cinven as they acquire additional shares in SYNLAB”, said Florian Feder, Managing Director at Rantum Capital. “Cinven has deep healthcare expertise and is the right partner to work with management on refocusing the company on its base business and improving profitability. The financing exemplifies Rantum Capital’s strength in providing leading companies in the DACH region with bespoke financing solutions.”
About Rantum Capital
Rantum Capital is a leading alternative investment platform focusing on the DACH mid-market. Its Private Debt Fund III provides financing solutions for M&A, growth and recapitalizations. Rantum typically invests between EUR 30-100m per transaction across senior debt, unitranche, second lien, and HoldCo PIK financings.
For more information visit www.rantumcapital.com.